The Influence of reduced susceptibility to fluoroquinolones in Salmonella enterica serovar Typhi on the clinical response to ofloxacin therapy

PLoS Neglected Tropical Diseases

Volumn 5, Issue 6, 2011, Pages

  Parry, Christopher M ^a,b   Vinh, Ha ^c   Chinh, Nguyen Tran ^c   Wain, John ^d   Campbell, James I ^a,b   Hien, Tran Tinh ^a,b   Farrar, Jeremy J ^a,b   Baker, Stephen ^a,b  

^a OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ABDOMINAL PAIN; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; CLINICAL FEATURE; CLINICAL PROTOCOL; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HEMATOCRIT; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SALMONELLA ENTERICA; SALMONELLA TYPHI; SEROTYPE; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; TYPHOID FEVER; VOMITING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; VIET NAM;

DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; SALMONELLA TYPHI; TREATMENT FAILURE; TYPHOID FEVER; VIETNAM;

EID: 79956287183     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001163     Document Type: Article

References (41)

1. Crump JA, Mintz ED, (2005) Global trends in typhoid and paratyphoid Fever. Clin Infect Dis 50: 241-246.
2. Parry CM, Threlfall EJ, (2008) Antimicrobial resistance in typhoidal and nontyphoidal salmonellae. Curr Opin Infect Dis 21: 531-538.
3. WHO (2003) The diagnosis, treatment and prevention of typhoid fever. Communicable Disease Surveillance and Response Vaccine and Biologicals pp. 7-18 (http://whqlibdoc.who.int/hq/2003/WHO_V&B_2003.2007.pdf).
4. Bethell DB, Day NPJ, Nguyen MD, et al. (1996) Pharmacokinetics of oral and intravenous ofloxacin in multidrug-resistant typhoid fever. Antimicrob Agents Chemother 40: 2167-2172.
5. Chau TT, Campbell JI, Galindo CM, van Minh Hoang N, Diep TS, et al. (2007) Antimicrobial drug resistance of Salmonella enterica serovar typhi in Asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. Antimicrob Agents Chemother 51: 4315-4323.
6. Chuang CH, Su LH, Perera J, Carlos C, Tan BH, et al. (2009) Surveillance of antimicrobial resistance of Salmonella enterica serotype Typhi in seven Asian countries. Epidemiol Infect 137: 266-269.
7. Kariuki S, Revathi G, Kiiru J, Mengo DM, Mwituria J, et al. (2010) Typhoid in Kenya is associated with a dominant multidrug-resistant Salmonella enterica serovar Typhi haplotype that is also widespread in Southeast Asia. J Clin Microbiol 48: 2171-2176.
8. Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ, (2002) Typhoid fever. N Engl J Med 347: 1770-1782.
9. Smith AM, Govender N, Keddy KH, (2009) Quinolone-resistant Salmonella Typhi in South Africa, 2003-2007. Epidemiol Infect 138: 86-90.
10. Renuka K, Kapil A, Kabra SK, Wig N, Das BK, et al. (2004) Reduced susceptibility to ciprofloxacin and gyra gene mutation in North Indian strains of Salmonella enterica serotype Typhi and serotype Paratyphi A. Microb Drug Resist 10: 146-153.
11. Roumagnac P, Weill FX, Dolecek C, Baker S, Brisse S, et al. (2006) Evolutionary history of Salmonella typhi. Science 314: 1301-1304.
12. Wain J, Hoa NT, Chinh NT, Vinh H, Everett MJ, et al. (1997) Quinolone-resistant Salmonella typhi in Viet Nam: molecular basis of resistance and clinical response to treatment. Clin Infect Dis 25: 1404-1410.
13. Keddy KH, Smith AM, Sooka A, Ismail H, Oliver S, (2010) Fluoroquinolone-resistant typhoid, South Africa. Emerg Infect Dis 16: 879-880.
14. British Society for Antimicrobial Chemotherapy (2010) BSAC Methods for Antimicrobial Susceptibility Testing. Version 9.1 http://www.bsac.org.uk/_db/_documents/Version_9.1_March_2010_final.pdf.
15. Clinical Laboratory Standards Institute (2010) Performance standards for antimicrobial sensitivity testing. Twentieth Informational Supplement. M100-S20. Volume 30 Villanova, PA CLSI.
16. British Society for Antimicrobial Chemotherapy (2010) BSAC Methods for Antimicrobial Susceptibility Testing. Version 9.1 http://www.bsac.org.uk/_db/_documents/Version_9.1_March_2010_final.pdf.
17. Cooke FJ, Day M, Wain J, Ward LR, Threlfall EJ, (2007) Cases of typhoid fever imported into England, Scotland and Wales (2000-2003). Trans R Soc Trop Med Hyg 101: 398-404.
18. Kapil A, Renuka, Das B, (2002) Nalidixic acid susceptibility test to screen ciprofloxacin resistance in Salmonella typhi. Indian J Med Res 115: 49-54.
19. Crump JA, Kretsinger K, Gay K, Hoekstra RM, Vugia DJ, et al. (2008) Clinical response and outcome of infection with Salmonella enterica serotype Typhi with decreased susceptibility to fluoroquinolones: a United States foodnet multicenter retrospective cohort study. Antimicrob Agents Chemother 52: 1278-1284.
20. Dutta P, Mitra U, Dutta S, De A, Chatterjee MK, et al. (2001) Ceftriaxone therapy in ciprofloxacin treatment failure typhoid fever in children. Indian J Med Res 113: 210-213.
21. Rupali P, Abraham OC, Jesudason MV, John TJ, Zachariah A, et al. (2004) Treatment failure in typhoid fever with ciprofloxacin susceptible Salmonella enterica serotype Typhi. Diagn Microbiol Infect Dis 49: 1-3.
22. Walia M, Gaind R, Mehta R, Paul P, Aggarwal P, et al. (2005) Current perspectives of enteric fever: a hospital-based study from India. Ann Trop Paediatr 25: 161-174.
23. Chinh NT, Parry CM, Ly NT, Ha HD, Thong MX, et al. (2000) A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever. Antimicrob Agents Chemother 44: 1855-1859.
24. Nguyen TC, Solomon T, Mai XT, Nguyen TL, Nguyen TT, et al. (1997) Short courses of ofloxacin for the treatment of enteric fever. Trans R Soc Trop Med Hyg 91: 347-349.
25. Smith MD, Duong NM, Hoa NT, Wain J, Ha HD, et al. (1994) Comparison of ofloxacin and ceftriaxone for short-course treatment of enteric fever. Antimicrob Agents Chemother 38: 1716-1720.
26. Vinh H, Wain J, Vo TN, Cao NN, Mai TC, et al. (1996) Two or three days of ofloxacin treatment for uncomplicated multidrug-resistant typhoid fever in children. Antimicrob Agents Chemother 40: 958-961.
27. Parry CM, Ho VA, Phuong le T, Bay PV, Lanh MN, et al. (2007) Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever. Antimicrob Agents Chemother 51: 819-825.
28. Vinh H, Duong NM, Phuong le T, Truong NT, Bay PV, et al. (2005) Comparative trial of short-course ofloxacin for uncomplicated typhoid fever in Vietnamese children. Ann Trop Paediatr 25: 17-22.
29. Cao XT, Kneen R, Nguyen TA, Truong DL, White NJ, et al. (1999) A comparative study of ofloxacin and cefixime for treatment of typhoid fever in children. The Dong Nai Pediatric Center Typhoid Study Group. Pediatr Infect Dis J 18: 245-248.
30. Clinical Laboratory Standards Institute (2006) Performance standards for antimicrobial disk susceptibility tests Approved Standard- ninth edition:. CLSI Document M2-A9 Villanova, PA CLSI.
31. Clinical Laboratory Standards Institute (2006) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: Approved Standard - seventh edition. CLSI document M7-A7 Villanova, PA CLSI.
32. Aarestrup FM, Wiuff C, Molbak K, Threlfall EJ, (2003) Is it time to change fluoroquinolone breakpoints for Salmonella spp.? Antimicrob Agents Chemother 47: 827-829.
33. Crump JA, Barrett TJ, Nelson JT, Angulo FJ, (2003) Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotype Typhi and for non-Typhi salmonellae. Clin Infect Dis 37: 75-81.
34. Parry CM, Thuy CT, Dongol S, Karkey A, Vinh H, et al. (2010) Suitable Disk Antimicrobial Susceptibility Breakpoints Defining Salmonella enterica Serovar Typhi Isolates with Reduced Susceptibility to Fluoroquinolones. Antimicrob Agents Chemother 54: 5201-5208.
35. Hasan R, Zafar A, Abbas Z, Mahraj V, Malik F, et al. (2008) Antibiotic resistance among Salmonella enterica serovars Typhi and Paratyphi A in Pakistan (2001-2006). J Infect Dev Ctries 2: 289-294.
36. Booker BM, Smith PF, Forrest A, Bullock J, Kelchlin P, et al. (2005) Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhi. Antimicrob Agents Chemother 49: 1775-1781.
37. Gaind R, Paglietti B, Murgia M, Dawar R, Uzzau S, et al. (2006) Molecular characterization of ciprofloxacin-resistant Salmonella enterica serovar Typhi and Paratyphi A causing enteric fever in India. J Antimicrob Chemother 58: 1139-1144.
38. Renuka K, Sood S, Das BK, Kapil A, (2005) High-level ciprofloxacin resistance in Salmonella enterica serotype Typhi in India. J Med Microbiol 54: 999-1000.
39. Dolecek C, Tran TP, Nguyen NR, Le TP, Ha V, et al. (2008) A multi-center randomised controlled trial of gatifloxacin versus azithromycin for the treatment of uncomplicated typhoid fever in children and adults in Vietnam. PLoS One 3: e2188.
40. Pandit A, Arjyal A, Day JN, Paudyal B, Dangol S, et al. (2007) An open randomized comparison of gatifloxacin versus cefixime for the treatment of uncomplicated enteric fever. PLoS One 2: e542.
41. Al Naiemi N, Zwart B, Rijnsburger MC, Roosendaal R, Debets-Ossenkopp YJ, et al. (2008) Extended-spectrum-beta-lactamase production in a Salmonella enterica serotype Typhi strain from the Philippines. J Clin Microbiol 46: 2794-2795.